AI Discovers New Hair Loss Drug: LCH34
Life Code shares poster from the 25th World Congress of Dermatology Singapore 2023 with Follicle Thought.
Artificial Intelligence Small Molecule Enhanced Hair Growth
Follicle Thought is pleased to share an exclusive look at Life Code’s poster from the current World Congress of Dermatologyevent. Just over a year ago, I shared anintroduction to Life Code, a Hong Kong-based drug discovery company which uses artificial intelligence to discover new molecules for various health conditions. Since then, Life Code has been quietly working on research programs for androgenetic alopecia and testing molecule candidates. The company used a proprietary AI drug discovery system, PetaPoly, to screen around 400,000 molecules, while looking for the best hair growth-inducing characteristics. From there, about 30 molecules with the best characteristics were further tested in vitro for efficacy, toxicity safety, and side effect potentials. One molecule was found to perform best across the board, LCH34, seen in the poster below. Note that this poster contains ex vivo human hair follicle (meaning follicles extracted from a human scalp) data from experiments carried out with the acclaimed contract research organization, the Monasterium Laboratory.
Life Code Seeking Partnership
Life Code has informed Follicle Thought that LCH34 is being developed as a pharmaceutical candidate treatment for androgenetic alopecia. To that end, they are seeking strategic partners in the pharmaceutical industry. Licensing inquiries can be made using the Contact link Life Code’swebsite. This poster displaying LCH34’s data is a great example of the work which happens behind the scenes after a company is first introduced to the hair-seeking internet crowd. Previously, Life Code was featured on Follicle Thought as a new company with research lines in AGA, and now a drug candidate is officially presented. There is still much work to be done, and hopefully human trials for LCH34 can be initiated in the near term.